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ABSTRACT
Using Biological Systems Theory (BST), our group builds intricate computer 
models of neurodegenerative diseases and associated processes to simulate 
the activities occurring within the cell regarding the disease of interest, utilizing 
CellDesigner 4.3 and MATLAB R2014a. This particular project primarily 
models Tau protein, as it is one of the most implicated proteins in Alzheimer’s 
disease. Intraneuronal hyperphosphorylated Tau protein leads to 
neurofibrillary tangles, which cause apoptosis. The model eventually resulted 
in the generation of optimal drug concentrations for molecules used 
theoretically as Tau protein kinase inhibitors, ultimately allowing the isolation 
of SP-600125 as the best mathematical solution to the biochemical problem 
presented in the form of our system of differential equations comprising 
aforementioned model. SP-600125 was determined as the best, but many 
other drugs performed well in this theoretical simulation of disease therapy.
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HISTORY
D em entia seem s to have been plaguing m ankind since A ncient Greece through 
the m odern era, its m ost extrem e case discovered and thence classified by Alois 
A lzheim er as A lzheim er’s disease in 1906 (AD 2013). Karl D eter, a m an o f  Frankfurt, 
G erm any brought his w ife, A uguste D eter, to a hospital for the m entally ill in 1901, 
w here she w as brought im m ediately to the director o f  said hospital, A lois A lzheim er. 
A  psychiatrist and neuropathologist, Dr. A lzheim er was quick to note in A uguste’s 
patient file that she was very advanced in her dem entia (AD 2013), especially  noting 
her sense o f  overw helm ing helplessness and inability to w rite despite her being a 
literate, 50 year old. Five years later, she passed away after experiencing severely 
w orsened sym ptom s including but not lim ited to illusions and hallucinations; 
A lzheim er and others were quick to exam ine her brain. His specific findings w ould 
lead to discovery o f  neurofibrillary tangles, the m am  biological association w ith the 
disease (AD 2013). D espite this association, there is currently no know n cure . .
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INTRODUCTION AND BACKGROUND
The nervous system  is w hat allow s the hum an body to com plete both voluntary 
and involuntary actions via the transm ission o f  electric signals. The brain is part o f  the 
central nervous system , or CNS. The hum an brain is com m only thought o f  as having 
three m ain parts: the forebrain, m idbrain, and hindbrain generally responsible for 
com plex thought processing, reflexes, and vital body functions respectively. The 
cerebrum  is also referred to as the cortex w hich is the outerm ost portion o f  the brain, 
consisting o f  the frontal, parietal, occipital, and tem poral lobes. The cerebrum , 
thalam us, and hypothalam us com prise the forebrain; the tectum  and tegm entum  
com prise the m idbrain; and the cerebellum , pons, and m edulla com prise the hindbrain. 
The thalam us and hypothalam us are part o f  w hat is referred to as the lim bic system, 
along w ith the am ygdala and m ost im portantly, the hippocam pus. The hippocam pus 
resides w ithin the m edial tem poral lobe and is associated with mem ory, and it is for 
th is reason that the cells o f  this brain com ponent are heavily investigated by scientists 
researching m em ory loss. A lzheim er’s disease researchers m ake particularly heavy 
use o f  hippocam pal cell lines, but that is not to say that these are the only types o f  cells 
affected by the disease.
A grey m atter type brain cell called a neuron has a cell body has a nucleus w ith 
expected organelles such as a golgi apparatus, ribosom es, and m itochondria. This cell
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body in turn receives inform ation from other neurons chem ically  via attached 
branching form ations called dendrites. D endrites, at specific points, are covered in 
receptors w hich receive inform ation in the form  o f  neurotransm itters released from 
neighboring neuron axonal synapses. Throughout the dendrites and axons alike are 
m icrofilam ents and m icrotubules w hich m aintain the ce ll’s structural integrity, ju st 
like that o f  any eukaryotic cell. M icrotubules play the largest cytoskeletal role here, 
and are kept together m ainly by m icrotubule-associated  proteins, or M APs. One o f  the 
m ost im portant types o f  M A Ps are the Tau variety, w hich play a m ajor factor in 
prom oting tubulin  assem bly into the m icrotubule m orphology (K oralova 2). H ow ever, 
in the neurons o f  people diagnosed w ith A lzheim er’s disease, tau proteins form 
aggregates and develop an inability to bind tubulin  through the norm al 
phosphorylation-regulated  method. The m icrotubules literally fall apart w ithout the 
integration o f  tau protein stabilizing them , resulting in neurodegeneration and cell 
death, w hich causes m em ory loss prim arily.
Tau Protein
Tau proteins are particularly large, ranging in m olecular weight betw een 
55,000 and 62,000 gram s per mole. They are rod-like in overall structure, and are tens 
o f  nanom eters in length on average. This length and size proves crucial in the binding 
o f  m icrotubules, especially in the rod-like shape o f  a neuronal axon (H irokaw a 1449). 
Tau proteins tend to act like short cross bridges, integrating them selves throughout the 
m icrotubule via dissem inated binding to the point w here the m icrotubule ascertains a
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slightly  higher elasticity. This elasticity allow s cross linking o f  m icrotubules, w hich 
provides healthy neurons w ith augm ented structural integrity (H irokaw a 1451).
Tau is not the only im portant M AP, but is m ost interesting because it seem s to 
have a large num ber o f  inherent properties, such as the fact that it is a natively 
unfolded protein (K oralova 2). This m eans that it can undergo m any transform ations 
or m odifications w hich result in varying degrees o f  conform ations. Researchers are 
actively try ing to discover w hich relationship, w hether it be phosphorylation, 
proteolysis, oxidation or glycosylation, is an active cause o f  the neurofibrillary build 
up as seen in AD patients.
Tau has m any phosphorylation sites on its unfolded native structure, m eaning 
that hyper-phosphorylation, w hen m ore phosphate groups bind than the substrate 
m olecule requires to perform  a specific function, certainly can occur (M andelkow  8 ). 
Phosphorylation o f  Tau usually results in 2 phosphate groups per Tau m olecule in 
healthy neurons, but AD diseased neurons typically show  upw ards o f  8 . H ow ever, it 
has been show n that this hyper-phosphorylation is not uncom m on in fetal neurons nor 
in anim als w hom  undergo hibernation, m arking it by m any as m ere coincidence. This 
has been supported by sim ilar levels o f  phosphatase and other enzym es who catalyze 
phosphorylation in hyper-phosphorylated cellular environm ents (M andelkow  9). 
H ow ever, it has also been shown that the hyper-phosphorylation o f  Tau proteins 
w eakens their affinity to m icrotubules, thus increasing the probability that Tau 
aggregations will form w ith an increased num ber o f  Tau -  Tau collisions occurring 
due to free Tau protein inside the cell. It is clear that both stances on Tau 
phosphorylation still need further study (M andelkow  9).
4
In addition to phosphorylation, Tau proteins often undergo proteolytic 
cleavage, w hich is the breakdow n o f  a protein into its consisting peptides and 
som etim es to the extent o f  am ino acid m onom ers. Proteases easily access the unfolded 
Tau and essentially cleave it into its sm aller pieces (M andelkow  10). Som etim es, 
how ever, it does not get entirely broken down; cysteine-aspartic proteases for exam ple 
cleave only the Tau tails, w hich in turn prevent its folding into conform ations proven 
less prone to aggregation. There are num erous exam ples o f  proteases, like this one, 
that are aggregation stim ulating in nature, but there are those w hich clip the Tau into 
potential configurations w hich have propensities to conform  structures w hich oppose 
Tau-Tau interlinking and therefore aggregation. The key here is to inhibit the 
aggregation stim ulating protease functions and stim ulate the aggregation inhibiting 
protease functions, w hich is easier said than done (M andelkow  10).
Tau proteins can also undergo oxidation. This occurs at the cysteine-322 
region o f  paired Tau helical filam ents. O xidation here allow s for disulfide bridging to 
m ore easily occur and dim er cross links to form  (M andelkow  10), heightening 
aggregation propensity  as well as essentially locking already aggregated Tau proteins, 
tw o results w hich are respectively negatively im pactful on diseased neurons.
Finally, the last prim ary transform ation undergone by m any Tau proteins is 
glycosylation. G lycosylation, being the process by w hich a carbohydrate is attached to 
a hydroxyl or o ther functional substituent o f  a m olecule, is norm ally a very good thing 
for Tau proteins because it protects against hyper-phosphorylation (M andelkow  10). I f  
the open sites to phosphorylation are not directly bound by carbohydrates through this 
process, steric interactions betw een bound carbohydrate chains and incom ing
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phosphates m ay be w hat decreases the likelihood o f  phosphate binding. H ow ever, in 
AD diseased neurons, glycosylated Tau proteins becom e defective regarding 
phosphorylation, stim ulating binding and thus increasing the propensity for hyper­
phosphorylation (M andelkow  10). The reason for these defectives arising is a 
currently  researched, unsolved mystery.
Since Alois A lzheim er’s tim e, it has proven difficult to identify causes or at 
least correlations betw een factors such as Tau proteins and A lzheim er’s disease. The 
results appear to be sporadic, in that there is a lack o f  com pelling evidence pointing 
tow ard genetic involvem ent, as 1-5% o f  all diagnosed have been deem ed so based on 
heredity. It seem s the best w ay to identify the disease in general, and thereby have a 
longer period to discover causes before death ensues, is through the seven stage 
process endorsed by the A lzheim er’s Association.
Seven Stages of Alzheimer’s Disease
The first stage is that o f  a norm al functioning hum an being w ho has zero 
im pairm ent w hatsoever despite uncom m on absentm indedness or even forgetfulness 
due to stress and other day to day factors. As previously described, som eone 
experiencing said m inor m ishaps w ould not be diagnosed w ith dem entia by a m edical 
professional, but perhaps som ething m ore along the lines o f  issues regarding the 
ability  to focus, pay attention, et cetera.
Stage two goes beyond the uncom m on mental m ishap to envelop the 
occurrences w hich involve im portant things such as the nam es o f  fam iliar objects and 
com m only used w ords o f  the pertinent language. These are described as m em ory
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lapses and are often noticed by the victim  o f  said lapses. Instances such as these would 
still be unclassified as dem entia by m edical professionals, and usually not noticed by 
relatives or persons o f  everyday contact.
Stage three is that o f  mild cognitive decline in w hich nam es are difficult to 
recall o f  new ly introduced persons, particularly  valuable objects are lost in the same 
proportion to those considered invaluable, and difficulty perform ing assigned tasks. 
O ften m ild cognitive decline results in m em ory loss o f  things that have ju st been read 
or seen and has also been associated w ith increasing difficulty regarding 
organizational skills and planning. M edical professionals w ould be able to diagnose 
som e m ild cognitive declining persons w ith early onset A lzehim er’s disease, but not 
all, some m ay be alternatively diagnosed w ith issues pertaining to concentration.
Stage four pertains to those persons w ith  m oderate cognitive decline.
Sym ptom s here include forgetfulness o f  recent events, inability to perform  challenging 
m ental arithm etic, m ore difficulty than m ild.cognitive declining persons regarding 
planning or social m anagem ent, and m ost im portantly, forgetting facts about on e’s 
own personal history. Previously, stages one through three involved potential 
forgetfulness regarding others or even surroundings, but stage 4 is clearly identified by 
rare forgetfulness o f  topics that a person should always know  about them selves. 
M edical professionals w ould diagnose a stage four person w ith either early-onset or 
m ild A lzheim er’s disease based on the com pilation o f  symptom s.
Stage five pertains to those persons w ith m oderately severe cognitive decline, 
m eaning that they have very externally noticeable gaps in m em ory and thinking 
ability. Sym ptom s include but are not lim ited to recalling a personal address or phone
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num ber, know ledge o f  the day’s date, inability to perform  non-challenging mental 
arithm etic, and inability to choose clothing pertinent to the weather. D iscerning stage 
five and beyond becom es increasingly difficult, so it is com m on to note things that 
persons in these stages are still able to do: stage five persons still rem em ber personal 
topics, how ever less so than stage four, and are still able to go to the bathroom  
unassisted. M edical professionals w ould now  be able to diagnose these persons w ith 
m oderate or m id-stage A lzheim er’s disease.
Stage six pertains to those persons severe cognitive decline. The experiences 
and sym ptom s that m ay be pertinent include forgetting w here one is or on e’s 
surroundings, strange personality  changes, needing help getting dressed entirely, 
changes in sleep patterns, delusional behavior, and frequent loss o f  bowel control. 
H ow ever, stage six is m ost often identified by ability to still rem em ber o n e ’s own 
nam e, despite loss o f  alm ost all personal history recollection. M edical professionals 
could diagnose a stage six person w ith m oderately severe A lzheim er’s disease.
The final stage is stage seven. Stage seven is the w orst step o f  the disease, as 
those afflicted experience very severe cognitive decline. Basically, in this stage, all 
ability to establish a long term  connection with their environm ent is lost. Some spurts 
o f  m em ory recollection have been noted, but are also all accom panied by another note 
saying that the same m em ory recollection happens often. Further, a very well o ff stage 
seven person m ay have an intriguing introduction and conversation w ith a healthy 
person, but then im m ediately forget the events w hich m ay have taken place seconds 
ago and attem pt to re-introduce his or herself as if  nothing ever happened. This is the 
best circum stance, w hereas the w orst o ff  stage seven persons cannot cloth, feed, nor
clean them selves w ithout assistance; many o f  the sym ptom s associated w ith 
A lzheim er’s disease are associated with those o f  an infant. This is not a coincidence, 
as things such as daily hygiene are learned and upon stage seven onset o f  AD, are fully 
unlearned and essentially destroyed cognitions.
In addition to severe social sym ptom s, severe physical sym ptom s are 
experienced by stage seven persons as well w hich delve beyond those experienced in 
infanthood, including loss or at least im paired m otor control. For exam ple, m any lose 
the ability to sw allow  food, som ething that is done regularly and naturally  by infants, 
despite their still relying on being fed in the first place. O thers lose the ability to react 
w ith  reflexes, sm ile, and even keep a straight neck before ultim ately losing all 
cognitive abilities and dying thenceforth.
Amyloid Beta Peptide
One o f  the m ost im plicated m olecules in AD neurodegeneration is the 
am yloid-beta (A(3) peptide. Ap is hydrophobic and can have a prim ary protein  
structure over 40 am ino acids long. It is the proteolytic result o f  A m yloid Precursor 
Protein (APP) cleavage by proteases such as p-secretase (L ichtenthaler 10). Currently, 
it is known that there are two m ajor com peting AD secretase pathways: the a-secretase 
pathw ay and the p-secretase pathway. The m inor pathw ay is o f  the y variety, 
appropriately  known as the y-secretase pathw ay. These pathw ays constitute w hat are c 
called the non-am yloidogenic and the am yloidogenic pathways.
The non-am yloidogenic pathw ay is responsible for 90%  o f  the APP cleavage 
activity, and is the pathw ay w hich does not lead to the generation o f  Ap. This pathw ay
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involves the m etalloprotease a-secretase cleaving APP to yield the shedding o f  a 
soluble APP fragm ent (sA PPa), leaving behind a carboxy term inal fragm ent (CTF) 
com posed o f  83 am ino acids w ith a C -term inus (C83). This a-secretase cleavage is 
follow ed by y-secretase cleavage o f  C83, resulting in a peptide fragm ent (p3) and 
another fragm ent referred to as the intracellular dom ain (AICD). These two resultant 
fragm ents are not know n to lead to Ap generation in any way, so the stim ulation o f  a- 
secretase activity is thought o f  as being highly therapeutic (L ichtenthaler 11).
The am yloidogem c pathw ay, correspondingly, is responsible for 10% o f  the 
A PP cleavage activity, and is the pathw ay w hich does in fact lead to the generation o f 
Ap. This pathw ay instead involves p-secretase cleaving A PP to yield the shedding o f  
sA PPp and C99. A fterw ards, y-secretase cleaves C99 in the same fashion as C83, but 
now  yields A ICD  and Ap. U pon secretion, soluble Ap is not as neurotoxic as the 
oligom ers w hich result from Ap m isfolding. These soluble, small oligom ers are 
associated w ith inflam m ation, inhibition o f  hippocam pal long term  potentiation, 
synaptic dysfunction, neuronal loss, and especially the form ation o f  neurofibrillary 
tangles (L ichtenthaler 10). Protofibrils are precursors to these tangles, w hich lead to 
neuronal cell death either directly by form ing fibrils or indirectly through pathogenic 
am yloid pores (PA P), w hich lead to reactive oxygen radical species (ROS). These 
resulting  high energy oxygen radicals are capable o f  directly causing aforem entioned 
neuronal cell death or indirectly causing it via activation o f  kinases involved w ith Tau 
protein activity.
Roles of the Endosomal System
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One organelle that has not been portrayed as m uch in the A lzheim er’s 
literature is the lysosome. The lysosom e is prim arily responsible for cellular waste 
rem oval in addition to cellular digestion o f lingering, unw anted chem ical compounds. 
It acts via hydrolytic enzym e secretion at a low, acidic pH  that is enclosed via its 
m em brane. This m em brane can fuse w ith other organelles and endosom e system s to 
engu lf the biochem ical m atter o f  interest, w hich can range from  foreign m icrobes to 
random  particles or m olecular debris.
The lysosom es o f  a neuron play a particularly im portant role in that they 
com prise w hat are know n as the endocytic and autophagic pathways. These pathw ays 
m ake synaptic transm ission o f  chem ical signals and neurotransm itters as well as the 
degradation o f  excess organic m aterials possible. A cceleration o f  endocytosis 
essentially can overw helm  the lysosom e and cause it to function improperly. This 
acceleration is caused by APP gene duplication that is a result o f  CTF accum ulation 
and is m ediated by rab5 (Pim plikar 14947). Essentially, efficiency begins to wane and 
proteolysis effectively halts, resulting  in m assive debris buildup w hich visibly swells 
neurons, changing their optim al conform ation. This buildup includes m olecules such 
as Ap, RO S, as well as other toxins that w ould have otherw ise been rem oved, to an 
extent, and thence results in neurodegeneration via m ultiple pathw ays (P im plikar 
14948). It is clear that this role as well as others m akes the lysosom e an organelle that 
should be considered m ore often w hen trying to unravel the m ysteries o f  AD 
neurodegenerative biochem istry. The internalized APP in particular participates in a 
vicious cycle o f  am yloidogenesis, generating m ore and m ore A p via the resultant
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sequestered fibril environm ent w hich has been shown to stim ulate the am yloidogenic 
pathw ay (B ahr 117).
A(3 can, however, be transported in other w ays into the cell. Extracellu lar Ap 
can bind to the a7-nicotin ic acetylcholine receptor, or a7nA ChR. This receptor is 
pentam eric and is a type o f  acetylcholine receptor found w ithin the brain, w hich 
triggers both presynaptic and postsynaptic excitation. W hen Ap binds, it com petes 
com petitively resulting in the slow ing and even prevention o f  calcium  activation and 
the release o f  acetylcholine (W ang 5626). One m ethod used to stop this binding is 
tak ing  advantage o f  a chem ical called alpha bungarotoxin, or a-BTX.
The a-B T X  drug is originally a com ponent o f  snake venom  w hich causes 
paralysis and respiratory failure by binding to neurom uscular nicotinic acetylcholine 
receptors. It has another role that is im portant in the unraveling AD therapies: its 
ability to bind a7nA C hR  in the brain (N agele 203). The 74 am ino acid that is 
otherw ise deadly can be thought o f  as an a lzheim er’s therapy in that it can com pete 
w ith Ap for b inding to a7nA C hR. The tricky part is not letting the toxin induce cell 
death while it prevents Ap binding, perhaps thw arted by anti-venom .
U pon binding o f  Ap to a7nA C hR , a com plex is form ed prim arily on neuronal 
dendrites w hich can then be transported inside the cell (Nagele 208). In addition to the 
lysosom e, early  and late endosom es play an extrem ely im portant role in AD neurons 
because they perform  said transportation and thus contribute to the internalization o f  
Ap. This can be thw arted by phenylarsine oxide, or PAO, w hich is an endocytosis 
inhibitor (N agele 201).
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Tau and Ap are indeed the two m ost im plicated proteins regarding the onset o f  
A lzheim er’s disease. H yperphosphorylated Tau protein leads to the form ation o f  
intraneuronal neurofibrillary tangles, w hich destabilize m icrotubules and result 
inevitably in apoptosis. Ap leads to the form ation o f  dim ers, protofibrils, and fibrils 
w hich form interneuronal senile plaques, disruption interneuronal com m unication and 
ultim ately inducing apoptosis as well. These two very im portant intraneuronal and 
interneuronal pathw ays respectively  are separated by the cell m em brane, but 
u ltim ately connected by intracellular Ap that has been internalized via m ethods 
described above. This connection arises and is founded on the fact that Ap stim ulates 
casein kinase I and casein kinase II (C hauhan 50). These two enzym es are called 
kinases because they perform  phosphorylation, specifically here on tau protein. The 
m ain focus o f  my research project thus far has been to study and unravel the 
relationships betw een such kinases and tau apoptosis by m athem atically  portraying the 
best way to lessen apoptosis both intraneuronally and m terneuronally. Before I talk  
about the m ethods, 1 w ould like to go give an in depth review  o f  the m etals, kinases, 
drugs, and other m olecules involved.
Roles of Metals
Let us not only look at the effects o f  peptides and organelles on AD, but also at 
the role m etals play in AD. I started w ith calcium  and learned that it had significant 
activity in aiding protein phosphatase 2A w ith dephosphorylating the 
hyperphosphorylated tau proteins characteristic in AD brains. I found it interesting 
that calcium  being one o f  the m ost readily accessible m etals in the body through
13
parathyroid horm one activity on bone cannot sim ply treat AD in this m anner. Aware 
o f  the new  ‘cocktail’ approach where it is thought that no one m olecule or drug can 
effectively cure a neurodegenerative disease, I knew  there m ust be another type o f 
m etal involved.
Zinc is a 3d transition m etal that is an essential m ineral to the hum an body. 
Z inc deficiency is m ore com m on than that o f  other m etals because the hum an body 
lacks a specialized zinc storage system. Zinc has im portant roles in grow th and the 
im m une system , but is also an im portant player w hen it com es to AD. Zinc has been  
found to catalyze the conversion o f  active PP2 A to inactive PP2A , as well as directly 
catalyze the hyperphosphorylation o f  Tau proteins (X iong 746). Thus, zinc seem s to 
be in com petition w ith calcium , as they have antonym ic effects on Tau proteins. 
H ow ever, rem em bering that it is an essential m ineral because o f  its o ther functions 
throughout the body, zinc is not to be elim inated from the diet as a potential 
therapeutic treatm ent. Instead, zinc intake by those w ith AD should be m inim ized to 
the low er end o f  recom m ended daily dietary allow ance (RDA) range, here being about 
9 m g/day. This com bined with other treatm ents could aid and indeed prove therapeutic 
for those with AD, based on these recent zinc findings.
Lithium  is the third elem ent o f  the periodic table and is the lightest metal in 
existence. It also is extrem ely reactive and flam m able. It has a w ide variety o f  
inorganic applications, ranging from its incorporation into therm onuclear w eapon fuel 
as lith ium - 6  deuteride to a source o f  electrons in galvanic cell batteries. There are 
som e bioorganic and m edicinal applications as well, including its use in the treatm ent 
o f  m ood disorders due to its involvem ent in the central nervous system  as a cation
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(Li+). In the brain, however, lithium has been show n to directly inhibit the beta 
isoform  o f  G lycogen synthase kinase -  3 Beta (G SK -3p) by com peting with 
m agnesium  (G ong 2323). As a result, a relative increase in lithium  could prove 
therapeutic in AD brains.
Roles of Tau Protein Kinases and Their Respective Activity Modulators
In addition to m etals, A lzheim er’s disease involves a variety o f  kinases and 
other m olecules that can be catalytic regarding the hyperphosphorylation pathw ay, as 
previously m entioned. Pharm acologically, it is m uch easier and m ore efficient to 
develop drugs w ith the ability to inhibit these catalysts as opposed to developing drugs 
w ith  the ability to activate inhibitors such as aforem entioned PPA2. Two o f  the m ost 
im portant kinase catalysts in general are cdk-5 and the aforem entioned GSK-3p, 
w hich are both proline directed protein kinases, or PDPKs.
GSK-3 is a protein  kinase that is associated w ith adding phosphates to proteins 
w ith threonine and serine prim ary protein structures, like those found in the tau 
protein. This enzym e was discovered and appropriately nam ed in 1980 for its 
regulatory involvem ent regarding glycogen synthase (Em bi 519). GSK-3 has an alpha 
and a beta form , denoted by G SK -3a and G SK -3p respectively, G SK -3p appears to be 
under m ore scrutiny than the alpha form for its im plication in A lzheim er’s disease 
(G ong 2323). Both form s o f  GSK-3 share m any inhibitors, including A loisine, 
H ym enialdisine, Induribins, and Flavopiridol, and aforem entioned Lithium  ju st to 
nam e a few.
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An aloisine has a m olecular form ula o f  C 16H 17N 3O and is a potent, perm eable
Figure 1
inhibitor o f  m any kinases, including GSK-3 (Gong
2323). They are 6 -phenyl[5H ]pyrrolo[2,3-b]pyrazm es, / = \
H 0 _ /  j  j
as seen in Figure 1, w hich act in an inhibitory fashion N %N
by com petitive ATP inhibition; this m eans that these m olecules inhibit the binding o f  
A TP to the catalytic portion o f  the kinase (M ettey 222). As a result, a relative increase 
in aloisine could prove therapeutic in AD brains.
A m ong other m olecules that are A TP-com petitive HyNs
inhibitors o f  GSK-3 are H ym enialdisine and Induribins, w hich HIM*
sure
•N
interestingly enough, are m arine- derived. H ym enialdisine, / /
\
HO
N X_^NH
portrayed by Figure 2, is a natural, m arine sponge m olecular h  //
0
product that has been show n to be inhibitory o f  GSK -3, am ong other kinases (M eijer 
51). It has three constituent N -heterocyclic rings in its 
structure that has m any analogues, a few  o f  w hich are 
acetylated or contain brom ine substituents (M eijer 51).
Indirubins are active ingredients in the Danggui Longhui W an, which is an ancient 
C hinese m edicinal recipe. These m olecules have four rings, as seen in Figure 3, two o f  
w hich are N -heterocyclic, and are also inhibitors o f  GSK-3 as well as other kinases 
(Leclerc 251). One induribin in particular is 6 -B rom oindirubin-3’-oxim e, or 6 -BIO. 
C rystallography o f  both hym enialdisine and induribins reveals that these ringed 
structures bind nicely to the ATP binding sites o f  GSK-3, m aking them  prim e targets 
for AD therapeutic approaches.
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Flavopiridol, seen in Figure 4 to the right, 
is a decently large alcohol with four rings, one o f 
w hich is N -heterocyclic. It has a chlorine 
substituent as well as a ketone. Its com m on nam e 
is A lvocidib, w here it and analogues are used to
IN
I
inhibit kinases other than GSK-3. H ow ever, it is 1
Figure 4
still thought o f  com m only as a GSK-3 inhibitor as well, proving as an effective 
treatm ent for AD and other taupathies (M artinez 377).
A R -014418, seen in Figure 5, is a GSK-3 chem ical inhibitor o f  the beta 
isoform  that has a urea foundation w ith term inal nitro and m ethoxybenzyl groups,
appropriately  called N -(4-M ethoxybenzyl)- ? J
n-N O
N '-(5 -m tro-l,3 -th iazo l-2 -y l)u rea. Its
m olecular w eight is 308 .31 g/mol and it has OCH3
an IC50 value o f  104nM  on GSK-3 beta. It is also active on CD K-5, but to a m uch , 
lesser extent, w ith an IC50 value o f  over 100 m icrom olar (M artin 292).
All o f  these inhibitors to the GSK-3 protein have been found to  be therapeutic 
in targeting tau  protein phosphorylation and hyperphosphorylation respectively, but 
m any o f  these inhibitors and other m olecules are also associated w ith CD K-5, another 
very im portant kinase involved in taupathy.
C yclin-dependent protein kinase 5 (cdk-5) is one o f  m any cyclin-dependent 
kinases (cdk), but is the m ost im plicated cdk in A lzheim er’s disease. This enzyme 
binds cyclin, a regulatory protein w hich com es in m any varieties ranging from cyclin
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A -  cyclin G, and then becom es able to phosphorylate proteins like Tau. In addition to 
aforem entioned inhibitors o f  GSK-3 like Flavopiridol, A loisine, and Induribins, CDK- 
5 has other inhibitors and inhibitor drugs, including O lom oucine, Roscovitine, 
Purvalanol, and Paullones. It has activators, some o f  w hich are p35 and p39 (Sausville
Cdk-5 cannot function m onom erically, for it depends specifically on activators. 
These aforem entioned activators can each be proteolytically  cleaved by calcium  
dependent calpains resulting in their sm aller form s nam ed p35 and p25, respectively. 
The cdk-5/p35 and cdk-5/p25 com plexes are m uch m ore active than  the cdk-5/39 and 
cdk-5/29 com plexes, contributing m oreso thusly to tau protein  hyperpho.sphorylation 
(M artin  292).
O lom oucine, or 2-(H ydroxyethylam ino)- Figure 6
been shown to regulate CDK-2 in the cell cycle, arresting cleavage in m any organism s 
(A braham  105). O lom oucine is portrayed in Figure 6 .
32).
especially in the brain. Interestingly, it has also
m any cyclin dependent kinases, but CDK-5
C 15H 18N 6O and is a com petitive ATP inhibitor o f
6-benzylam ino-9-m ethylpurine, has form ula
butanol, 6-(B enzylam ino)-2(R )-[[l 
very sim ilar m olecule in structure to olom oucine, is
o therw ise know n as 2-(R )-[[9 -(l-M ethy lethy l)-6 -
[(phenylm ethyl)am ino]-9H -purin-2-y l]am ino]-l-
R oscovitine (or Seliciclib), seen in Figure 7, is a
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(hydroxym ethyl)propyl]ainino]-9-isopropylpurine with form ula C 19H 26N 6O. They can 
be easily distinguished by the extra ethyl group o ff  the benzylic nitrogen in 
Roscovitine. It is also sim ilar in function to olom oucine, as it inhibits CDK-5 
substantially  and in a sim ilar m anner. Interestingly enough, roscovitine too plays a 
role in the cell cycle, proving to be a useful antim itotic reagent (Borgne 527).
Purvalanol differs in structure w hen 
com pared generally to olom oucine and roscovitine, Figure 
but still m aintains the core double N -heterocyclic
ring system . The two form s, Purvalanol A and j p 1 1 /
NO-, *
Purvalanol B, portrayed by Figures 8  and 9
"-N,
Cl
v  > r
I ^
H , /
respectively, can be readily distinguished by observing that Purvalanol B has a
benzylic acid group in its chem ical structure, 
as it is form ally nam ed 2-chloro-4-[(2- 
{[(2R)- 1 -hydroxy-3-m ethylbutan-2- 
yl]am ino}-9-(propan-2-yl)-9H -purin-6- 
y l)am ino]benzoic acid w ith chem ical 
form ula C 20H 25CIN 6O 3 Purvalanol A,
Figure 9
H~C.
C H
how ever, ju s t has a chlorine substitutent on that particular benzene group. Purvalanol 
in general inhibits m any cyclin- dependent kinases (V illerbu 761), and has been used 
specifically  as a CDK-5 inhibitor. It has been shown to decrease Ser-522 and Thr- 
514/409 levels specifically, the residues that have com m only been linked to tau 
protein  hyperphosphorylation sites (Cole 18230).
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Paullones are tetracyclic, fused 
com pounds that cover a large range o f  
derivatives w ith d ifferent purposes, many 
o f  w hich include being inhibitory regarding 
cdks and GSK-3 (M artinez 377). They 
generally are not sim ilar in structure to 
olom oucine, roscovitine, nor purvalanol other than the fact that there are still two N - 
heterocyclic rings. These two rings are not exactly the sam e as those found in the other 
three m olecules due to one o f  them  being 8  m em bered instead o f  6  m em bered. A 
specific type o f  paullone called alsterpaullone, was show n to be specifically 
im plicated in the reduction o f  tau phosphorylation (Selem ca 959) and is portrayed 
chem ically by Figure 10.
R -C R 8  , or (2-(R )-(l-ethyl-2-hydroxyethylam ino)-6-(4-(2-pyridyl)benzyl)-9- 
*
isopropylpurine) is an interesting
m olecule portrayed by Figure 11 
w hich has the exact sam e structure as 
roscovitine in that the only difference 
is an extra quinolone substituent 
attached to the benzene group. That
u
H
being said, it is specifically  a derivative o f  (R )-roscovitine that is thought o f  as a 
versatile inhibitor because it acts on both CD K-5 and GSK-3 (M artin  297).
It seem s that generally, a double, fused quinolone N -heterocyclic  ring sytem at 
the core o f  a chem ical is necessary or at least beneficial to its action as a CDK-5
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inhibitor, especially for those w hich are ATP com petitive. This structure, or one that is 
sim ilar, appears in m any o f  the drugs that are being designed for this purpose, and 
should be m aintained in the developm ent o f  drugs specifically designed for AD 
therapy to m inim ize tau protein phosphorylation and hyperphosphorylation.
CDK-5 and GSK-3 m ay be the m ost generally well know n kinases involved in 
neurodegenerative diseases, but casein kinases are particularly im portant in 
A lzheim er’s disease and my research project specifically, as previously m entioned. 
C asein kinases are non-proline directed protein kinases, or non-PD PK , and have two 
m am  types each w ith its ow n isoforms.
Casein Kinase 1, or CK1 has 7 d ifferent isoform s know n as C K l-a , C K l-p , 
C K l-y l ,  C K l-y2 , C K l-y3 , CK 1- 5, and C K l-£  w hich range in m olecular w eight from 
25 to 55 kDa. The C K l-a , CK 1- 5, and C K l-£  isoform s are involved specifically in 
A lzheim er’s disease (M artin 298). These three isoform s are also referred to as 
CSN K 1A 1, C SN K 1D , and CSN K 1E respectively and are know n to phosphorylate tau 
protein.
Casein K inase 2, or CK2 has three isoform s, CK 2- a, C K 2 -a ’, and CK2-p. 
CK 2- a  and C K 2 -a ’ are involved in A lzheim er’s disease and are also referred to as
i
CSNK2A1 and C SN K 2A 2 respectively. Both phosphorylate tau, while each also has 
an interestingly unique additional function: CK 2- a activates PP2A  and CK 2- a ’ 
inhibits PP2A  (M artin 298). PP2A  is a protein  phosphatase, w hich effectively has a 
reverse kinase effect on tau protein by rem oving phosphate.
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Both CK1 and CK2 proteins undergo aforem entioned activation by Ap, but are 
also subject to inhibition by several chem icals including H eparin, TBCA, and IC261 
w hich interestingly differ greatly in structure.
H eparin, seen structurally in Figure 12, is a 
relatively large m olecular w eight drug averaging 
around 13.5 kg/mol that has forever been used in a 
sulfated form  to act as an anticoagulant. However, 
since the 1980s, H eparin has been show n to be an 
effective inhibitor o f  C K 2-a and C K 2 -a ’ CK-2 
variants. (H athaw ay 8040).
Tetrabrom ocinnam ic acid, or TBCA, is portrayed by Figure 13 and is a small 
drug com pared with the inhibitors acting on GSK-3 and CD K-5, with system atic nam e 
(2E )-3-(2,3,4,5-Tetrabrom ophenyl)acrylic acid. Its 
m ain features are the four brom ines on the phenyl
0
'OH
group w hich are com plem ented by the acid group on X X  ^
Br 'f Figure 13
the other end o f  the m olecule. It is exceptionally  m ore gj*
potent o f  an inhibitor on CK2- a, C K 2 -a ’, and CK2-P than on C K l-a , CK 1- 8 , and
C K l-a , but is regardless an inhibitor o f  both types o f  casein kinases (M artin 298).
IC261, or l,3-D ihydro-3-[(2 ,4 ,6- 
trim ethoxyphenyl)m ethylene]-2H -indol-2-one, is a 
chem ical that effectively inhibits C K l-a , CK 1- 8 , and 
C K l-e , but has a particularly potent activity on CK 1- 8 , 
w ith  a rem arkable IC50 o f  ju st 1.0 m icrom olar (M artin
O C H
uri
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298). It is easily distinguished structurally  by its sym m etrical trim ethoxyphenyl group 
and has a m olecular w eight o f  311.33 g/mol.
Tau Tubulin K inase, or TTBK , is another non-proline directed protein kinase 
that is also know n as B rain-D erived Tau Kinase, or BDTK. There are two varieties o f  
TTBK, called Tau Tubulin K inase-1, or TTBK-1 and Tau Tubulin  K inase-2, or 
TTBK-2. TTBK-1 and TTB K -2 are very sim ilar in catalytic -  dom ain structure and 
are specific to the brain, expressed in cortical neurons and hippocam pal neurons 
respectively (Sato 1573). Together these kinases phosphorylate tau at 10 different 
phosphorylation sites, often catalytically rely ing on M g2+ and M n2+ cations to deposit 
the phosphate (Sato 1580). TTBK-1 and TTBK-2 are indeed identified as im portant 
targets for A D  therapy, but no TTB K  chem ical inhibitors have been discovered nor 
synthesized to date.
D ual-Specificity  Tyrosine-(Y )-Phosphorylation Regulated Kinase, or DYRK, 
is yet another non-proline directed protein kinase that has 6  d ifferent isoforms. The 
tw o isoform s actually involved in A lzheim er’s disease are D ual-Specificity  Tyrosine- 
(Y )-Phosphorylation Regulated K inase-1A (D Y R K  1 A) and D ual-Specificity  
Tyrosine-(Y )-Phosphorylation R egulated K inase2 (DY RK 2). Interestingly, 
chrom osom e 21 contains a gene on 21q22.2 w hich encodes DYRK1 A; this is very 
im portant because chrom osom e 2 1  is involved in D ow n’s syndrom e and m ay be 
linked to the neurofibrillary tangles found w ithin D ow n’s syndrom e patients (M artin 
298). Both D Y R K 1A  and D Y RK 2 phosphorylate tau protein but are relatively unique
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regarding the other kinases m entioned in that they can prim e other kinases to act w ith 
augm ented efficiency. D Y RK s are also able to undergo tyrosine auto-phosphorylation 
to achieve activation. One very potent chem ical inhibitor is known, called Harmine. 
H arm ine, seen in Figure 15, is an alkaloid chem ical that is also called
pyrido[3 ,4-b]-indole and has a m olecular w eight o f
212 .25 g/mol. It has a relatively small chem ical structure com posed m ainly o f  three 
fused rings. H arm ine is m ost com m only know n for its ability to inhibit m onoam ine 
oxidase A (M A O -A ), w hich is an enzym e that breaks dow n m onoam ine com pounds. 
Som e exam ples o f  m onoam ines are serotonin, norepinephrine, and psilocybin w hich 
are independently classified as a type o f  neurotransm itter, horm one, and recreational 
drug respectively. In addition to this effect, how ever, H arm ine has been used as an 
anticancer as well as an inhibitor to D Y RK  1 A. Harm ine does in fact inhibit other 
D Y R K s including D Y RK 2, but m ost effectively inhibits D Y R K 1A  w ith an IC50 value 
o f  80 nM (M artin  298).
E xtracellular signal-regulated kinases (ERK s) are m itogen-activated protein 
kinases that are proline-directed. There are two isoforms, both o f  w hich are involved 
w ith AD: E xtracellu lar signal-regulated kinase-1, or ER K 1, and E xtracellular signal- 
regulated kinase-2, or ERK2. They are also know n as M APK 3 and M A PK 1,
Telepathine. It is a naturally occurring com pound Figure 15
that is found in the M iddle Eastern plant Peganum
harmala. Its IUPA C nam e is 7 -M eO -l-M e-9H -
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respectively. ER K s have one m ain activator and one m ain inhibitor, referred to as 
Paclitaxel and FR 180204 respectively.
Paclitaxel, seen in Figure 16, is a chem ical activator o f  ERKs that is also 
com m only referred to as Taxol or Onxal. Its IUPA C nam e is (2a,4a,5p ,7p ,10p ,13a)- 
4 ,10-B is(acety loxy)-13-{ [(2R,3S)-3-
large in size com pared w ith  drugs
Figure 16
discussed so far. It is a naturally  occurring com pound, being isolated from  tree bark o f  
the organism  Taxus brevifolia, but is currently developed com m ercially  after being 
totally  synthesized in 1994. Paclitaxel is m ost com m only know n for its anticancer 
properties, having been discovered officially in 1962 and thence utilized by the United 
States N ational C ancer Institute and other H ealth  O rganizations. It is technically a 
cytoskeleton toxin, as cells treated w ith the drug exhibit serious deficiencies in 
chrom osom e segregation and m itotic cell division. This is because in addition to its 
activation o f  ERK, w hich could lead to heightened phosphorylation and eventual 
apoptosis, it over-stabilizes m icrotubule polym ers by binding beta-tubulin  m icrotubule 
subunits (Low e 1046). This m icrotubule stability seem s like a positive attribute 
regarding the reduction o f  cell death, but very stabilized m icrotubules have trouble 
during disassem bly, thus disrupting mitosis. D isrupted m itosis eventually leads to cell 
death. Therefore, paclitaxel would definitely have the negative effects o f  cell death
en-2 -yl benzoate and is relatively
dihydroxy-9-oxo-5 ,20-epoxytax-11 
phenylpropanoyl]oxy} -1,7-
(benzoylam ino)-2-hydroxy-3 
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that are situational ly taken advantage o f  w hen fighting cancer, but i f  adm inistered to a 
person w ith AD, the m icrotubule stabilizing effects could be advantageous. Such 
investigations into the efficacy o f  paclitaxel on neurodegenerative m em ory loss are 
being conducted at institutions across the country, including The U niversity  o f 
Pennsylvania.
ERKs also have an inhibitor, nam ed FR 180204.
Its IPUA C nam e is 5-(2-Phenyl-pyrazolo[l,5 - 
a]pyridm -3-yl)-lH -pyrazolo[3 ,4-c]pyridazm -3-yIam m e 
and its m olecular w eight is 327.34 g/mol. F R 180204 is 
a potent inhibitor o f  ERK1 w hen com pared to its 
efficacy at inhibiting ERK2, w ith IC50 values o f  0.310 m icrom olar and 0.806 
m icrom olar respectively (M artin  298). F R 180204 is portrayed by Figure 17.
P38s are m itogen-activated protein kinases that are involved in apoptosis and 
differentiation o f  cells. There are four isoform s, p38- a, p38- p, p38- y, p38- 5 and are 
referred to as M A PK 14, M A P K 11, M A PK 12, and M APK 13 respectively. P38 
phosphorylates tau at 2 1  different sites upon activation, which occurs via auto- 
phosphorylation or in the presence o f  extracellular stress 
(M artin  297). P38 has a potent inhibitor called SB-239063, 
show n structurally  in Figure 18.
SB-239063, or trans-4-[4-(4-F luorophenyl)-5-(2- 
m ethoxy-4 -py rim id iny l)-lH -im idazo l-l-y l]cyclohexanol, is a 
selective inhibitor o f  p38 w ith an IC50 value o f  0.044
j g u r e  I B
OMe
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m icrom olar and a m olecular w eight o f  368.41 g/mol.
C -Jun N -term inal Protein K inases (JN Ks) are m itogen activated protein 
k inases (M A PK ) w ith 10 different isoforms. The three m ain types w hich collectively 
house these ten isoform s are JNK1 (M A PK 8), JN K  2 (M A PK 9), and JN K  
3(M A PK 10). The first two are found in m ost tissues throughout the body including the 
brain, w hile JNK3 is alm ost exclusively found in brain tissue. JNKs range in size from 
45 to 55 kD a and phosphorylate tau protein at 12 different sites, and is inhibited by 
protein  phosphatases and especially by a chem ical called SP600125 (M artin  297).
SP600125, show n in Figure 19, is a chem ical 
inhibitor o f  the three aforem entioned JN K  types.
D epicted  to the right, its formal nam e is A n th ra[l-9 -cd ]- 
pyrazol-6(2H )-one, but is m ore com m only referred to as 
1,9-Pyrazoloanthrone or sim ply A nthrapyrazolone. This 
chem ical has a m olecular w eight o f  220.23 g/mol and has 
an IC50 value o f  0.090 m icrom olar tow ard JNK3. It is
Figure 19
very slightly m ore potent, how ever, at inhibiting JNK1 and JNK2 w ith respective 
IC50 values each at 0.04 m icrom olar (M artin 297).
NH
Protein K inase A, or PICA, is an enzym e tetram er w hose regulatory subunits 
require cyclic AM P, or cAM P, binding to induce enzym atic activation. It is for th is 
reason that PK A  is also com m only know n as cA M P D ependent Protein Kinase. PK A 
phosphorylates 17 im portant sites along tau protein associated with AD brains, and
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thusly can be considered an important target for AD therapy by inhibitors. The most 
important inhibitor o f  PKA activity is H-89 (Martin 299).
H-89, or N-[2-broinocinnamylamino)ethyl]-5-isoquinoline sulfonamide
dichloride hydrate, seen in Figure 20, is a 
potent PKA inhibitor with an interesting 
structure, roughly the size o f  an ATP 
molecule. Thusly, it inhibits PKA by
Figure 20
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Figure 21
A T P
acting in competition with ATP with 
isoquinoline mimicking adenosine, 
sulfonamide m imicking ribose, and 
bromobenzene m imicking the ATP
phosphates seen in Figure 21 (Lochner 265). The isoquinoline group o f  FI-89 is 
certainly not the exact same size as the 
adenosine portion o f  ATP, but 
crystallography shows it is similar enough 
to bind PKA, in place o f  adenosine, around 
the amino acid Val 123 (Engh 876). After 
determining where the sulfonamide binds,
Engh et al. attempted but were not able to 
identify the exact crystallographic position o f  the bromobenzene electron density 
portion o f  H-89 binding, but they were in fact able to conclude that it was located 
roughly within the region where the ATP phosphates otherwise would bind. They 
depict the two best H-89 bindings to PKA in Figure 22.
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Protein Kinase B, or PKB, is also known as Akt and has three main isoforms, 
Protein Kinase B - a  (PKB-a), Protein Kinase B - (3 (PKB-(3), and Protein Kinase B - y 
(PK B -y)  or A k t-1, Akt-2, and Akt-3 respectively. PKB overexpression is known to 
cause tau hyperphosphorylation at the main threonine and serine residues, threonine 
212, serine 214, and 396 respectively (Martin 299). These three isoforms activate 
GSK-3[3 and also have an inhibitor, Akt VIII trifluoroacetate hydrate salt.
Akt VIII, seen in Figure 23, inhibits all three isoforms but is more selective 
toward Akt-1, with an IC50 value o f  58 nM 
compared to the larger 2 lOnM IC50 value and 
even larger 2100nM  IC50 value for Akt-2 and 
Akt-3. The salt is formally named 1,3-Dihydro- 
1 -(1 -((4-(6-phenyl-1 H-imidazo[4,5- 
g]qumoxalm-7-yl)phenyl)methyl)-4-piperidinyl)- 
2H-benznnidazol-2-one, corresponding to its 
large quinoxaline ringed chemical structure.
Interestingly, it is PKB specific in concentrations below 50 micromolar, but inhibits 
PKA and PKC at concentrations above 50 micromolar (Martin 300).
Protein Kinase C, or PKC, is one o f  the most diverse protein kinases in that it 
has over fifteen isoforms, but for simplicity, but can be classified into three broad 
categories: conventional, novel, and atypical. Conventional PKCs include the four 
isoforms PKC-ol PKC-f31. PKC-p2, and PKC-y. These isoforms require DAG and 
calcium ion to function. Novel PKCs include the seven isoforms PKC-8, PKC-51,
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PKC-52, PKC-63, PKC-e, PKC-q, and PKC-O. These novel isoforms require DAG but 
do not require calcium ion to function. The remaining five isoforms that are referred to 
as atypical include the following: PKC-i, PKC-£, PK-N1, PK-N2, and finally, PK-N3. 
These five are referred to as such because they are not like the rest, for they require 
neither calcium ion nor DAG to function. In my model, DAG is incorporated 
mathematically as an activator as it is required by the majority o f  PKC isoforms to 
function. Bisindolylmaleimide I is also incorporated, as it is a potent chemical 
inhibitor o f  PKC (Martin 300).
Diacylglycerol, or DAG, seen in Figure 24, is from a fundamental biological 
perspective is a type o f  molecule also called diglyceride that is involved in
?
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biochemical signaling o f  secondary messages. One particular DAG involved in PKC 
signaling is a long lipid that is formally called l-palmitoyl-2-oleoyl-glycerol. The 
D A G  is found in the cell membrane, and the conventional and novel PKCs bind DA G 
to achieve activation and thence ability to phosphorylate substrate, such as Tau 
protein. I f  the PKC is indeed conventional, calcium ions from the inositol 
triphosphate, or IP3, intermembrane channel belonging to the endoplasmic reticulum 
will need to be provided via release into the cytosol. IP3 is a chemical that will always 
be present as long as DAG is present in the cell membrane, because it is a byproduct 
o f  Phospholipase C, which is an enzyme that cleaves IP3 from phosphatidylinositol 
4,5-bisphosphate, or PIP 2 , to form DAG fundamentally. Ligands need to bind a
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surface receptor to stimulate this entire pathway secondary messenger signaling 
pathway.
Bisindolylmaleimide I, or 
GF-1, seen in Figure 25 is a C}
chemical inhibitor o f  PKC. Its 
formal name is 3-[ 1 -[3- 
(d im ethylam ino)propyl]-lH -indol-
3-yl J-4-( 1 H-indol-3-yl)-1H-
pyrrole-2,5-dione and the chemical y /
\
has a truly fascinating structure . ..... \
with near symmetrical dual indole
substituents coming o ff  o f  a main unsaturated double y-lactam. GF-1 is a potent 
inhibitor o f  the conventional PKCs with 1C50 values less than 21 nM. It can also 
inhibit the novel PKCs, exhibiting IC50 values below 200 nM. It does not do well 
with the atypical PKCs, whereas GF-1 is only able to inhibit 50% o f  PKC-^ with a 
concentration o f  5800 nM (Martin 
300). Another important modulator 
o f  PKC activity is Bryostatin I, 
seen in Figure 26.
Bryostatins are very large 
lactones that inhibit PKC.
Originally, Bryostatins were 
naturally isolated from the Bugiila
H OH
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neritina , which are a species o f  aquatic invertebrates called bryozoan. There are 
currently over 19 Bryostatins that have been isolated or synthesized. They were first 
employed as anti-cancer agents, but are to date being investigated in 
neurodegenerative diseases such as A lzheim er’s disease. Bryostatin 1, involved in AD, 
has the formal name (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,20R,23R,25S) -25- 
A cetoxy-1,11,20-trihydroxy-17-[( 1 R)-l -hydroxyethyl]-5,13-bis(2-methoxy-2- 
oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo- 
[21.3.1.13,7.111,15] nonacos-8-en-12-yl (2E,4E)-2,4-octadienoate.
There are other kinases o f  course, but these are the ones that I have targeted as 
having the highest potential for proving therapeutic regarding the treatment o f  
A lzhe im er’s disease.
Molecules involved in the phosphatase pathway:
Protein Phosphatase 2 (PP2A) was mentioned with regards to zinc and the 
casein kinases above, but not fully explored. This protein is directly involved in 
removing phosphate groups from proteins like Tau at the serine and threonine residue 
regions; therefore, it is a catalyst o f  tau dephosphorylation. It has been shown to be 
upregulated by lithium in the rat frontal cortex and hippocampus (Tsuji 413). It is 
heterotrimeric in structure, comprised o f  a heterodimeric core enzyme and a subunit 
that provides regulation. The heterodimeric portion is comprised o f  a catalytic subunit 
and a scaffolding subunit, respectively, in addition to being supported by M g2+ 
coenzyme (Xu 1239).
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oPP2A is the major tau phosphatase in the
H
brain but should be used with caution as it is N
H
more broad in its substrate specificities than N O
protein kinase inhibitors, which could lead to
negative, unforeseen side effects (Gong 2326). Two inhibitors regulate PP2A activity, 
known as I iPP2A and W P2A respectively. Melatonin, seen in Figure 27, is otherwise 
known as N-acetyl-5-methoxytryptamine or N-[2-(5-methoxy-l H-indol-3-yl)ethyl], 
and acts in a reverse manner and thus restoring PP2A activity (Gong 2327). However, 
melatonin could have other side effects upon tau hyperphosphorylation reversal due to 
its widespread hormonal abilities that have been prescribed to treat or subdue 
circadian rhythm sleep disorders, immune disorders, and cardiovascular disorders, as 
well as sexual dysfunction.
Okadaic acid seen in Figure 28, is a well-known marine-derived toxin named 
after the species Hahchondria okadai, a type o f  sea sponge. It is a relatively large 
molecule that is in fact produced by algae and plankton. It is formally a toxin with
0  H X  -e— «  OH
HQ""
V , ,  P tT  '" V -  w : w
H
v °
QH *
chemical name (2R)-3-[(2S,6R,8S,l lR)-2-[(E ,lR)-3-[(2S,2& prnneR ,4R,4aS,6R,8aR)-
4-hydroxy-2-[( 1S,3S)-1 -hydroxy-3-[(2S,3R,6S)-3-methyl-l ,7-dioxaspiro[5.5]undecan- 
2-yl]butyl]-3-methylene-spiro[4a,7,8,8a-tetrahydro-4H-pyrano[2,3-e]pyran-6,5'- 
tetrahydrofuran]-2'-yl]-l -methyl-prop-2-enyl]-l 1 -hydroxy-4-methy-l-l ,7- 
dioxaspiro[5.5]undec-4-en-8-yl]-2-hydroxy-2-methyl-propanoic acid. Okadaic acid
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does not act directly on tau protein, but mathematically has the same effect as tau 
phosphorylation by instead acting to non-competitively inhibit PPA2. Upon ingestion 
o f  the toxin, in addition to the inhibition o f  Ser/Thr phosphatases such as PP2A in 
places like brain hippocampal neurons, Okadaic acid causes diarrheal shellfish 
poisoning, or DSP (Kamat 164). This occurs in the intestinal tract, in which Okadaic 
acid inhibits the removal o f  phosphate to induce more permeability along 
gastrointestinal cell membranes, hence diarrhea as a symptom. One chemical which 
seems able to reverse the negative effects o f  Okadaic acid is memantine.
M emantine is an N-methyl-D-aspartate , or
n h 9
N M D A , receptor agonist that modulates PP2A 
signaling. Its IUPAC name is 3,5- 
d im ethyltricyclo[3.3.1.13,7]decan-lam ine and is 
named such because o f  the triple fused saturated ring 
system seen to the right in Figure 29.
It blocks over-activated N M D A  receptors and thus prevents excite-toxicity (Li 
268). In moderate to severe AD, memantine prevents tau hyperphosphorylation in 
hippocampal neurons (Gong 2324).
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METHODS
A sim plified m odel o f  A lzheim er’s disease was m ade via the program  Cell 
D esigner4.2 using tau protein literature regarding m olecular links to 
hyperphosphorylation. Below, in Figures 31 and 32, are snapshots o f  two o f  the most 
im portant processes in the graduate student version o f  the model. They are not true
Figure 30
snapshots, but rather cleaned up versions because the real model has becom e so 
com plex that it is difficult to visually interpret, as evident in Figure 30 above.
35
dk-5 monomerdk-5 monomer
-5 m onom er:dk-5 m onom er)
£dk-5  m onom er) m onom er jZM
£dk-5  m onom er) Ip25:dk -5 mo nome
m onomer :dk-5 m onom er
As seen here in Figure 31, CDK-5 complexes o f  four varieties
hyperphosphorylate Tau protein. Generally throughout the whole model, the dark
green as seen here is consistent with the color for all o f  the tau protein kinases, and the
dark blue also as seen here is consistent with the inactive forms o f  said kinases. The
shiny red color o f  the tau proteins here is consistent with the entire pathway from tau
to NFT formation, microtubule destabilization, and ultimately apoptosis. Lines that
jo in  to form a single filled arrow were chosen to be indicative o f  heterodimer
association or complex formation. Other regular filled arrows were chosen to be
indicative o f  transition states from molecule to molecule, whereas lines with unfilled
circular ends were chosen to be indicative o f  activation. The caveat here is that the
molecules exhibiting lines with unfilled circular ends activating the process o f
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inactivation were later integrated as inhibitors o f  the species undergoing said 
inactivation. This is seen, as one might expect, with R-CR8 and Seleciclib. They are 
both chemical inhibitors o f  the four CDK-5 complexes, but it was more convenient in 
CellDesigner to portray them as activating the process o f  kinase inactivation.
Fibril
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Figure 32
As seen here in Figure 32, the non-amyloidogenic pathway to the right o f  APP 
and the amyloidogenic pathway to the left o f  APP, resulting in aforementioned 
Extracellular Amyloid Beta 42 and eventual apoptosis via the senile plaque formation 
cascade. The senile plaque cascade is portrayed in lime green while the extracellular 
secretases are in a softer green. The amyloid is internalized via complex formation and 
endocytotic vesicle transport throughout the cell. The resultant intracellular amyloid 
then leads to the tau hyperphosphorylation pathway, thus triggering apoptosis. The 
trigger arrow is the type with an unfilled arrowhead and perpendicular line just 
beneath the arrowhead, signifying that there are aforementioned molecular pathways
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taken in between to reach the molecule or process being triggered. The transport arrow 
looks the exact same as the trigger arrow, but it has a filled arrowhead. The inhibitor 
'a r ro w ’ is not quite an arrow as much as a line with a small perpendicular end It is 
seen regarding bungarotoxin and PAO above.
After the molecular modeling, Biological Systems Theory (BST) was used to 
make sense o f  the above complexity exhibited by the model as a whole. Originally 
developed by Eberhard Voit, BST allows theoretical biochemists to use ordinary 
differential equations to model cell activity mathematically. Our group employed 
m any o f  the same BST methods described in a previous Coleman group, Sass et al. 
(2009), but the main difference is that ours used Michaelis equations, Hill equations, 
and real numerical values as inputs instead o f  theorized estimated values for the first 
time ever. We also used the more current and updated program M ATLAB version 
R2014a instead o f  PLAS
To acquire these values and thereby mathematically model the neuron with 
true, real-life accuracy, large databases o f  proteins and drugs alike such as BREND A 
and M O PED  were scoured that ultimately resulted in a whole spreadsheet full o f  
formal name listings, LC50 values, IC50 values, initial concentrations, and rate 
constant values. Most o f  the time, these values were found cited as being from frontal 
lobe brain tissue, which was especially helpful.
With a full set o f  values and coded system o f  equations, our group set out to 
find the specific set o f  drug concentrations which would be therapeutic in reducing the 
am ount o f  tau protein hyperphosphorylation and thereby a theoretical treatment for
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A lzheim er’s disease. Computational healthy cell and diseased cell states were 
constructed, then drugs were selected.
Figure 34 below is a snapshot o f  the Hill equations implemented. Each line o f  
code after the tdea th=’ portion is for a specific drug, utilizing a specific LD50 value. 
These Hill equation variants are o f  the form 
l / ( l+ e A(Tox-[Drug])), where tox=LD50 and 
Drug is the drug concentration from the list in 
Figure 33 that uses dynamic_concentration as a 
tool for calling from said list. Drugs taken into 
account here were SP-600125, R-CR8, 6-BIO,
AR-A014418, SB-239063, paclitaxel, heparin, 
bryostatin, harmine, seleciclib, and alpha BTX.
Other drugs were not included for various 
reasons, ranging from our group deeming them 
as drugs that are unfit for this study or simply 
ones where LD50 values do not currently exist in 
the literature due to lack o f  clinical trial testing. The beauty here is that different drugs 
can easily be added or subtracted from the equation when the need presents itself or 
when one wants to change the parameters o f  the study. Ultimately this set o f  equations 
uses lethality data to produce a semi-sigmoidal dose-response curve for every single 
drug incorporated into the equation set.
(13 4) = SO; .
(13 6) = 5; % 6
(13 9) = 310;
(142) = 660; 
( 1 4 5 )  = SO; %;
(14 9) = 10; %-
i j  — z B i;
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Figure 35 below is a sample snapshot o f  how michaelis menten kinetics 
variants were used to mathematically model the enzyme catalyzed tau 
phosphorylation. Km ATPs were used instead o f  Km tau for simplicity purposes. 
A lm ost every line in the code here represents a kinase that is acting on tail protein. 
Equation portions with irrational e ’s in them represent the drugs acting on the kinases, 
which can be easily turned on and o ff  via commenting and uncomm enting in 
M ATLAB syntax "%' to produce a variety o f  different data regarding the changing 
variable o f  interest, which in this figure is hyperphosphorylated tau arbitrarily vailed 
variable X(99).
40
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To control the parameters o f  the plots generated from the combined death 
function equations and michaelis kinetics equations incorporated into the code, an 
advanced plotting tool seen in Figure 35 was utilized, as seen partially in the snapshot 
Figure 36 below. The “+, o, *, etc” are all strings used to denote different drugs, 
assigned arbitrarily as the plotter receives them, allowing us to distinguish one drug 
from another drug. The most important portions o f  this code are the resolution and the 
range.
The resolution is essentially the number o f  points that are plotted, 
appropriately giving enhanced resolution when this num ber is increased. This is 
especially important for plots which do not appear contiguous upon initial inspection, 
the resolution can be increased to reveal the activity o f  the drug in areas unclear on the 
graph. The catch here is that for every order o f  magnitude one increases resolution, the 
computational time for generating the plot o f  interest increases proportionally. This
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leads to some intensely long sessions o f  plotting just to make sure some drugs do not 
have extraneous local minimum cell death Y-axis values that do not initially appear.
Figure 36
X , '  p
x
x f 3 5 , * d 5 , ' '
re3ciutron=1000;
val_r r . ul t ip l i5r=l i ! ;3pace  (0, n , r e so lu t i o n )  ; Fxrxx range :x rx,;X.: r c 1 r er 
X _ c= ze rc 3 ( r e s o l u t i o n ,15);
Y_ g= ze r os ( r e so lu t i o n , 15);
x v a lu e s = l i n s p a c e (0 ,50000 , r e s o l u t i o n ) ; xccn: 
fo r  i = (-4j
for  j = l : r e s o l u t i o n
xva l*va l  r e u l t i p l i e r  ( j )*drug i n i t i a l s  ( i ) ; I r a a l a  >rralue.e t a aa a  or:
■IX''al-~'X'xalues •: j ) ;
drug used=drug params;
drug u s e d (i ) =xva l ;
yval=death_cutput(drug u se d ) ;
X _g( j , i )=x va l ;
Y_g(1 , i ) =yva l ;  
ox o x;; ■ =xr"-~ 1;
VY a i  a l . ;
legend e n t r y ( i ) = p lo t (X  g (j , i ) , Y_g (j , 1 ; , s t y l e ( i ) ,* c o l o r c o l o r s  ( i , : ) ) ;
o o:aoo: a or:ox: xr ae
The range is simply computed using “xvalues=linspaee(0 ,15000,resolution)” 
but can also be computed using “val_multiplier=linspaee(0,7,resolution);” , which 
essentially automatically chooses a range from 0 to a multiplier o f  the d rug’s IC50 
value, in this case being 7 times. Changing the 0 and 15000 values in the first case 
simply determines the concentration o f  the drug on the X-axis. This allows one to 
instantly locate the region o f  the graph where the supposed LD50 value is and make 
sure it is behaving properly. The range also works in tandem with the resolution, for
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when the range is shortened more data can be plotted without changing the resolution 
to a higher, computationally expensive value. The key here is to use both the 
resolution and the range as efficiently as possible to find apoptosis minima.
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RESULTS
The following Figures 37 -  58 are the results gathered from M ATLAB plotting 
functions. Figures 37 and 38 show constructed healthy and diseased states, while 
Figures 39 -  57 show graphs o f  the selected drugs with concentration versus apoptosis 
relative value. Figure 58 is essentially a table with all o f  the important data tabulated 
and further discussed in the discussion section.
Figure 37: Healthy State
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Figure 38: Diseased State
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Drugs Plotted with Concentration(nM ) versus Apoptosis 
SP-600125 Plots
Figure 39: SP-600125 Concentration Range 0:700 nM (~7x IC50)
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Figure 40: SP-600125 Concentration Range 210:235 nM with minimum
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(R)-CR8 Plots
Figure 41: (R)-CR8 Concentration Range 0:900 nM (~7x IC50)
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Figure 42: (R)-CR8 Concentration Range 360:430 nM with minimum
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6-BIO Plots
Figure 43: 6-BIO Concentration Range 0:35 nM (~7x IC50)
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Figure 44: 6-BIO Concentration Range 9.8:10.7 nM with minimum
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AR014418 Plots
Figure 45: AR014418 Concentration Range 0:800 (~7x IC50)
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Figure 46: AR014418 Concentration Range 220:245 nM with minimum
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SB-239063 Plots
Figure 47: SB-239063 Concentration Range 0:4500 (not effective)
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Paclitaxel Derivative (Hypothetical) Plots
Figure 48: Paclitaxel Derivative Concentration Range 0:8000 (~x25 IC50)
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Figure 49: Paclitaxel Derivative Concentration Range 2650:2900 with minimum
0 .1 6 9 3
0 .1 8 9 3
0 .1 8 9 3
0 .1 6 9 3
0 .1 6 9 3
0 .1 8 9 3
0 .1 6 9 3
0 .1 6 9 3
0 .1 8 9 3
0 .1 6 9 3
0 .1 6 9 3
□
X: 2 7 6 9 .5 1 9 5 1 9 5 1 9 5 2  
Y: 0 .1 6 9 3 0 4 6 0 6 9 5 5 8 8 3
2 6 5 0 2 7 0 0 2 7 5 0 2 8 5 0
50
Heparin Plots
Figure 50: Heparin Concentration Range 0:7000
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Figure 51: Heparin Concentration Range 1650:2150 with minimum
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Harmine Plots
Figure 52: Harmine Concentration Range 0:5000
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Figure 53: Harmine Concentration Range 200:380 with minimum
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Seleciclib Plots
Figure 54: Seleciclib Concentration Range 0:9000 (~30x IC50)
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Figure 55: Seleciclib Concentration Range 400:900 with minimum
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Brysostatin Plot (High Toxicity Plot)
Figure 56: Bryostatin Concentration Range 0:2000
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Alpha BTX Plot (Toxin Plot)
Figure 57: Alpha BTX Concentration Range -80:60
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Figure 58: Table of Minima Compared to LD50 Values and Apoptosis Rankings
%
Minimum 
o f  LD50
Apoptosis Apoptosis
M olecule o f LD50 (nM)
M inimum Relative Value Rank
Interest (nM) Lowest to 
Highest
SP-600125 2500.00 225.135 9.005 0.1723165 2
(R)-CR8 6960000.00 400.800 0.006 0.1763066 5
6-BIO 9000.00 10.300 0.114 0.1763112 7
AR014418 320910.00 228.820 0.071 0.1763109 6
SB-239063 6921.82 _ _ _ _ _ _ — 9
Paclitaxel 
4 Derivative ’ 38857.71 2769.519 7.127 0.1693046 1
Heparin 211555.00 1870.870 0.884 0.1757427 3
Harmine 1170000.00 287.387 0.025 0.1761241 4
Seleciclib 1010000.00 614.414 0.061 0.1763113 8
Brvostatin 76.64 _ _ _ _ _ _ _ _ _
Alpha-BTX 10.22 - - - _ _ _ — —
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DISCUSSION
Figures 37 and 38 show the theoretical constructed healthy and disease states 
respectively. Everything is within a few order o f  magnitudes, which is accurate for 
resting concentrations o f  molecules within the cell. The disease state shows the value 
o f  hyper tau to be over almost 15x the value o f  hyper tau in the normal state, at a 
resounding 15.181818 nM. This is the hyper tau increase which is responsible for the 
neurofibrillary tangles.
Figures 39 through 57 show the apoptosis versus concentration plots for each 
drug, starting from relative apoptosis value at approximately 0.176325. This value is a 
relatively arbitrary value used as a value that seems to make simple sense. All the cells 
cannot die, but a large portion must die for the memory loss to occur. 0.176325, being 
between 10 and 20% is a good estimation, seeing that AD brains shrink by 
approximately that percentage compared to non-diseased patient brains. A tedious 
algorithm o f  finding the minimum apoptosis value was enacted via running the code 
on different concentration ranges at varying resolutions to find the best minimum.
After many hours o f  generating plots using some o f  the highest resolutions that even a 
computer with 16 individual core processors can handle, the minima were all located 
on the drugs which worked and were tabulated in Figure 58.
Figure 58 shows each molecule o f  interest’s determined minimum 
concentration (X-coordinate) and database LD50 value. It also shows the apoptosis 
m inimum  value (Y-coordinate). None o f  the apoptosis values diminish by a great 
percentage. Some appear to not shrink at all from the mtitial 0.176325 value upon
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initial inspection. This is because some o f  our toxicity levels, tau in particular, are set 
to counter the effects o f  many drugs in tandem, not individually. This is a great way to 
discover the drugs which do not work the best, seen by SB-239063 in Figure 47 
because it does not even have a value that begins to decrease apoptosis under the 
computationally imposed toxicity stresses. Thus the drugs do not appear effective 
numerically until the differences between the values are taken into consideration; 
everything is relative here. Additionally, rankings are assigned based on the lowest 
and highest resultant apoptosis values.
The green shaded values under each column represent the best value in that 
column. In the M inim um  column, the green shaded value represents the lowest drug 
concentration used. The shaded green values under the % M inim um  o f  LD50 column 
represent the drug effectiveness in that those drugs shaded were effective at reducing 
apoptosis with very low concentration percentage o f  their LD50 value.
Paclitaxel is shaded blue because I wanted to implement a random neutral 
hypothetical molecule into the model. Ignoring its potential therapies as a microtubule 
stabilizer, if Paclitaxel was an inhibitor instead o f  an activator, the values generated 
are reported in Figure 58 The lowest apoptosis value mean that a very similar 
derivative that functions oppositely to Paclitaxel may prove therapeutic regarding the 
parameters and considerations o f  this study. Essentially, this is demonstrating the 
power o f  BST m odeling and endless hypothetical possibilities that can be incorporated 
into future work.
Alpha-BTX was incorporated into the model to show that it is indeed a toxin 
and also to portray what the graph o f  a toxin would look like compared to the other
57
drugs, as seen in Figure 57. Similarly, however, bryostatin 1 in Figure 56 shows 
reverse activity, despite it being a potent PKC inhibitor. This is due to its very small 
LD50 value, a value that is only lOx the LD50 o f  A lpha-BTX at 77nM. Essentially the 
cell dies before the therapeutic effects take place, so it portrays behavior similar to a 
true toxin. Alpha-BTX and Bryostatin 1 and accordingly both shaded red in Figure 56, 
m eaning that they are not therapeutic in the slightest.
The best mathematical solution to the problem o f  A lzheim er’s disease 
apoptosis presented by this model and set o f  system o f  differential equations is SP- 
600125. It simply has the best apoptosis relative value, excluding hypothetical 
paclitaxel derivative. Even though its % M inim um  o f  LD50 is the worst relatively, it is 
still below 10% o f  the LD50 value, coming in at 9.005. The second best choice is 
Heparin, which has the second best apoptosis relative value excluding hypothetical 
paclitaxel derivative, and interestingly enough, has one o f  the lower % M inimum of 
LD50 values. An alternative, if one is only interested in % o f  LD50, is Harmine, as it 
achieves the third lowest apoptosis relative value excluding hypothetical paclitaxel 
derivative while maintaining the lowest % o f  ED50 concentration required to achieve 
said minimum.
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CONCLUSION
Using biological systems theory (BST), it has been confirmed that most o f  
these drugs perform their preconceived functions regarding inhibition and activation 
o f  tau protein kinases. It has been concluded that SP-600125 is the best mathematical 
choice for A lzheim er’s disease therapy. It has also been concluded that Heparin and 
Harmine are the alternative situational mathematical choices for A lzheim er’s disease 
therapy. It has additionally been concluded that bryostatin is a pseudo toxin, 
resembling alpha-BTX in that it is too toxic to portray therapeutic results 
mathematically. It has also been concluded that SB-239063 is the worst choice for a 
drug that does not act as a pseudo toxin.
Methods such as those conducted by this research group utilizing BST are 
providing the essential theoretical information to start cutting edge research projects 
around the globe in effort to slow the progression if find the elusive cure to this deadly 
disease, as it can be one o f  the worst to watch happen. It can occur very early in life 
relative to the current life expectancies o f  our era, and last for a long time thereafter, 
proving challenging for caregivers. Caregiving is the last resort after treatments and 
other m anagement techniques are applied. In terms o f  medicated prevention, no 
medication has been proven statistically, totally effective, resulting in alternative 
methods, ranging from mentally stimulating activities to ultrasound technology.
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